The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s ...

A drug once intended to treat diabetes, Halicin, is showing new promise as a potent weapon against multidrug-resistant (MDR) ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

A new study published in Current Molecular Pharmacology explores the transformative role of large language models (LLMs) in drug development. The research highlights how LLMs enhance efficiency and ...

AI in Cancer Drug Discovery could prove paradigm shifting, but what challenges does it present? And how can they be avoided?

A newly discovered receptor switch that boosts bone growth could transform how we treat osteoporosis, by stimulating the body ...

One of the main factors determining therapeutic antibodies’ half-life is the interaction between the antibody’s Fc region and ...

In the battle against aggressive breast cancer, a once-elusive target is now within reach—thanks to a breakthrough from a ...

Cell models are replacing animal testing in pharma. Explore expert tips on transitioning to more accurate, ethical and ...

Lowering drug development costs The urgency for such approaches is driven by the astronomical cost of gene-editing therapies.

YourChoice Therapeutics, working with Quotient Sciences and Incyte, reports that single oral doses of the investigational non ...

Pharmaceutical companies, including AbbVie and Amgen, are driving clinical research on DLL3 -targeted therapies, and several drug candidates are already in advanced stages of development.